Sight Sciences publishes investor presentation on interventional glaucoma, dry eye platforms
Reuters2026/08/05 22:34- Sight Sciences outlined a strategy to expand procedural eye-care offerings across glaucoma and dry eye, targeting earlier intervention versus daily eye drops.
- Management flagged a return to double-digit revenue growth in 2026, supported by strong gross margins and disciplined operating expense control.
- TearCare reimbursement progress highlighted, with the first two Medicare Administrative Contractors establishing fee schedules to support market access.
- Installed base cited at more than 400,000 interventional glaucoma procedures, more than 75,000 interventional dry eye procedures performed to date.
- Dry eye market size estimated at USD 2.4 billion in the US, versus a USD 6 billion addressable US glaucoma market with more than 4 million diagnosed patients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen consolidates near August highs vs USD as hawkish BoJ, Fed bets clash
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Crypto prices
More
